In ovarian cancer patients, there were 52.94% (9/17) and 75.0% (6/8) of pathogenic variants were distributed in exon 14 of BRCA1 and exon 11 of BRCA2, respectively (Fig. 3C). This evidence concerns the gene BRCA2 and ovarian cancer.